SK16052002A3 - Enantioméry 2-aminotetralínových derivátov, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie - Google Patents
Enantioméry 2-aminotetralínových derivátov, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie Download PDFInfo
- Publication number
- SK16052002A3 SK16052002A3 SK1605-2002A SK16052002A SK16052002A3 SK 16052002 A3 SK16052002 A3 SK 16052002A3 SK 16052002 A SK16052002 A SK 16052002A SK 16052002 A3 SK16052002 A3 SK 16052002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- enantiomers
- chf
- methylaminotetralin
- pharmaceutical compositions
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 230000008569 process Effects 0.000 title claims abstract description 8
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical class C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 15
- BHDFPNRSDABMPW-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1CC(NC)CC2 BHDFPNRSDABMPW-UHFFFAOYSA-N 0.000 claims abstract description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 22
- 238000006722 reduction reaction Methods 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000001631 hypertensive effect Effects 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- OMMYLOLVPCCZQZ-AWEZNQCLSA-N [(6s)-6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1C[C@@H](NC)CC2 OMMYLOLVPCCZQZ-AWEZNQCLSA-N 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 230000000707 stereoselective effect Effects 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims 1
- OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- MIMDMPWWTWVHFK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrochloride Chemical compound Cl.C1=CC(O)=C(O)C2=C1CC(NC)CC2 MIMDMPWWTWVHFK-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FQHKWDHSEAGKNM-UHFFFAOYSA-N 4-(2,3-dimethoxyphenyl)-2-(methoxycarbonylamino)butanoic acid Chemical compound COC(=O)NC(C(O)=O)CCC1=CC=CC(OC)=C1OC FQHKWDHSEAGKNM-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000004659 Presynaptic Receptors Human genes 0.000 description 3
- 108010003717 Presynaptic Receptors Proteins 0.000 description 3
- TWTMQRXNAZGSCE-PFEQFJNWSA-N [(6r)-6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;hydrochloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1C[C@H](NC)CC2 TWTMQRXNAZGSCE-PFEQFJNWSA-N 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- LKQPSXAEAAEUCE-UHFFFAOYSA-N methyl n-(5,6-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)carbamate Chemical compound C1=CC(OC)=C(OC)C2=C1CC(NC(=O)OC)CC2 LKQPSXAEAAEUCE-UHFFFAOYSA-N 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- HVKPFRTYUYTGFO-UHFFFAOYSA-N 5,6-dimethoxy-n-methyl-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=C(OC)C2=C1CC(NC)CC2 HVKPFRTYUYTGFO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- TWTMQRXNAZGSCE-UQKRIMTDSA-N [(6s)-6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;hydrochloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1C[C@@H](NC)CC2 TWTMQRXNAZGSCE-UQKRIMTDSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- -1 isobutyroyl Chemical group 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- XVVNIBWOAAEHBD-UHFFFAOYSA-N methyl n-(5,6-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-n-methylcarbamate Chemical compound C1=CC(OC)=C(OC)C2=C1CC(N(C)C(=O)OC)CC2 XVVNIBWOAAEHBD-UHFFFAOYSA-N 0.000 description 2
- NWABBOAPGNNYAP-UHFFFAOYSA-N methyl n-(5,6-dimethoxy-1-oxo-3,4-dihydro-2h-naphthalen-2-yl)carbamate Chemical compound COC1=CC=C2C(=O)C(NC(=O)OC)CCC2=C1OC NWABBOAPGNNYAP-UHFFFAOYSA-N 0.000 description 2
- CRWACYYGENOWCW-UHFFFAOYSA-N methyl n-[2-(2,3-dimethoxyphenyl)-5-oxo-2h-furan-4-yl]carbamate Chemical compound O1C(=O)C(NC(=O)OC)=CC1C1=CC=CC(OC)=C1OC CRWACYYGENOWCW-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- BHDFPNRSDABMPW-QMMMGPOBSA-N (6s)-6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1C[C@@H](NC)CC2 BHDFPNRSDABMPW-QMMMGPOBSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZROCNTZTEKIWKT-UHFFFAOYSA-N 4-(2,3-dimethoxyphenyl)-2-oxobut-3-enoic acid Chemical compound COC1=CC=CC(C=CC(=O)C(O)=O)=C1OC ZROCNTZTEKIWKT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- GOTMKOSCLKVOGG-UHFFFAOYSA-N SCH 23390 Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC=C1 GOTMKOSCLKVOGG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- OMMYLOLVPCCZQZ-CQSZACIVSA-N [(6r)-6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1C[C@H](NC)CC2 OMMYLOLVPCCZQZ-CQSZACIVSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002562 anti-bronchospastic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 238000011916 stereoselective reduction Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001053A IT1318516B1 (it) | 2000-05-12 | 2000-05-12 | Derivati 2-amminotetralinici otticamente attivi, procedimenti per laloro preparazione e impiego terapeutico delle corrispondenti |
| PCT/EP2001/005212 WO2001085668A1 (en) | 2000-05-12 | 2001-05-08 | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16052002A3 true SK16052002A3 (sk) | 2003-03-04 |
Family
ID=11445033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1605-2002A SK16052002A3 (sk) | 2000-05-12 | 2001-05-08 | Enantioméry 2-aminotetralínových derivátov, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040102652A1 (xx) |
| EP (1) | EP1280759A1 (xx) |
| JP (1) | JP2003532700A (xx) |
| KR (1) | KR20020094014A (xx) |
| AR (1) | AR028097A1 (xx) |
| AU (1) | AU2001274000A1 (xx) |
| BG (1) | BG107259A (xx) |
| BR (1) | BR0110989A (xx) |
| CZ (1) | CZ20023718A3 (xx) |
| HU (1) | HUP0302027A2 (xx) |
| IL (1) | IL152751A0 (xx) |
| IT (1) | IT1318516B1 (xx) |
| NO (1) | NO20025393L (xx) |
| PL (1) | PL357466A1 (xx) |
| SK (1) | SK16052002A3 (xx) |
| TN (1) | TNSN01072A1 (xx) |
| WO (1) | WO2001085668A1 (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| EP1384708A1 (en) * | 2002-07-26 | 2004-01-28 | CHIESI FARMACEUTICI S.p.A. | Process for the manufacture of form I of nolomirole hydrochloride |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214156A (en) * | 1988-03-25 | 1993-05-25 | The Upjohn Company | Therapeutically useful tetralin derivatives |
| IT1269584B (it) * | 1994-04-26 | 1997-04-08 | Chiesi Farma Spa | Procedimento per la preparazione di derivati di 5,6-diidrossi- 2-ammino-1,2,3,4- tetraidronaftalene |
| IT1275935B1 (it) * | 1995-03-17 | 1997-10-24 | Chiesi Farma Spa | Derivato di aminotetralina per la terapia di malattie cardiovascolari |
| IT1313583B1 (it) * | 1999-07-30 | 2002-09-09 | Chiesi Farma Spa | Derivati 2-amminotetralinici per la terapia del glaucoma. |
-
2000
- 2000-05-08 IL IL15275100A patent/IL152751A0/xx unknown
- 2000-05-12 IT IT2000MI001053A patent/IT1318516B1/it active
-
2001
- 2001-05-08 SK SK1605-2002A patent/SK16052002A3/sk not_active Application Discontinuation
- 2001-05-08 BR BR0110989-8A patent/BR0110989A/pt not_active Withdrawn
- 2001-05-08 JP JP2001582269A patent/JP2003532700A/ja active Pending
- 2001-05-08 HU HU0302027A patent/HUP0302027A2/hu unknown
- 2001-05-08 PL PL01357466A patent/PL357466A1/xx not_active Application Discontinuation
- 2001-05-08 AU AU2001274000A patent/AU2001274000A1/en not_active Abandoned
- 2001-05-08 US US10/275,894 patent/US20040102652A1/en not_active Abandoned
- 2001-05-08 WO PCT/EP2001/005212 patent/WO2001085668A1/en not_active Application Discontinuation
- 2001-05-08 CZ CZ20023718A patent/CZ20023718A3/cs unknown
- 2001-05-08 EP EP01940415A patent/EP1280759A1/en not_active Withdrawn
- 2001-05-08 KR KR1020027014884A patent/KR20020094014A/ko not_active Application Discontinuation
- 2001-05-11 TN TNTNSN01072A patent/TNSN01072A1/fr unknown
- 2001-05-11 AR ARP010102255A patent/AR028097A1/es not_active Application Discontinuation
-
2002
- 2002-11-08 BG BG107259A patent/BG107259A/bg unknown
- 2002-11-11 NO NO20025393A patent/NO20025393L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003532700A (ja) | 2003-11-05 |
| NO20025393L (no) | 2003-01-13 |
| IL152751A0 (en) | 2003-06-24 |
| CZ20023718A3 (cs) | 2003-02-12 |
| WO2001085668A8 (en) | 2002-02-21 |
| ITMI20001053A1 (it) | 2001-11-12 |
| TNSN01072A1 (fr) | 2005-11-10 |
| US20040102652A1 (en) | 2004-05-27 |
| BG107259A (bg) | 2003-07-31 |
| WO2001085668A1 (en) | 2001-11-15 |
| KR20020094014A (ko) | 2002-12-16 |
| AU2001274000A1 (en) | 2001-11-20 |
| PL357466A1 (en) | 2004-07-26 |
| NO20025393D0 (no) | 2002-11-11 |
| AR028097A1 (es) | 2003-04-23 |
| BR0110989A (pt) | 2003-12-30 |
| ITMI20001053A0 (it) | 2000-05-12 |
| EP1280759A1 (en) | 2003-02-05 |
| HUP0302027A2 (hu) | 2003-10-28 |
| IT1318516B1 (it) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4842963B2 (ja) | 糖尿病を処置するｄｐｐ−ｉｖ阻害剤としての置換ベンゾキノリジン | |
| US20060009479A1 (en) | Process for the synthesis of hydromorphone | |
| SK3612000A3 (en) | Sustained release tablet formulation to treat parkinson disease | |
| WO1989001472A1 (en) | Melatonin analogues | |
| EP1096926B1 (en) | Methods and compounds for treating depression | |
| JP2001514632A (ja) | 新規ヘテロサイクリック化合物 | |
| BRPI0812919B1 (pt) | composição farmacêutica que compreende um composto e kit | |
| JPH10512252A (ja) | １−（３，４−ジクロロベンジル）−２−メチルアミノインダンの鏡像異性体 | |
| SK16052002A3 (sk) | Enantioméry 2-aminotetralínových derivátov, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie | |
| EP0001021B1 (fr) | Nouveaux dérivés d'alcaloides pentacycliques, procédé de préparation, application à la synthèse de produits du groupe de l'éburnamonine et compositions pharmaceutiques | |
| EP0053964A1 (fr) | Médicaments à base de dérivés de (quinolyl-4)-1 éthanol ou propanol, nouveaux dérivés de (quinolyl-4)-1 éthanol ou propanol et procédés pour leur préparation | |
| JPS61165324A (ja) | 心臓脈管系疾患治療剤 | |
| EP0671173A1 (fr) | Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs | |
| EP2128137A1 (en) | Selective m4 receptor antagonist and its medical use | |
| EP0463970A1 (fr) | Nouveaux dérivés d'oxazolo pyridines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| EP0405344B1 (en) | 2-amino-1,2,3,4,-tetrahydronaphthalene derivatives with cardiovascular activity, process for their preparation and pharmaceutical compositions containing them | |
| JP3782445B2 (ja) | 尿失禁を処置するためのキノロン誘導体 | |
| US5405872A (en) | Anti-hypertensive tetralins | |
| US4543361A (en) | ±2-[Phenethyl]-5-[(3,4-methylenedioxy)-α-hydroxybenzyl]pyrrolidine antihypertensives and use thereas | |
| EP1476433B1 (fr) | Nouveaux derives de tricyclo-imidazolines, leur procede de preparation et leur utilisation a titre de medicaments | |
| KR0148755B1 (ko) | 신규 테트라하이드로이소퀴놀린계 화합물 및 그의 염 | |
| FR2500823A1 (fr) | 1-aminoalkyl-1, 2, 3, 4-tetrahydroanphtalenes mono- ou disubstitues utiles notamment comme adrenergiques et medicaments les contenant | |
| NZ199008A (en) | 2,3,3a,4,5,6-hexahydro-ih-indolo(3,2,1-de)(1,5)-naphthyridines | |
| NZ267427A (en) | Optical isomers of 4(5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole, preparation thereof | |
| JPS59161381A (ja) | ±２−〔フエネチル〕−５−〔（３，４−メチレンジオキシ）−α−ヒドロキシベンジル〕ピロリジン類 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |